AI Article Synopsis

  • Cystoid macular edema (CME) is a rare eye condition that can occur from taxane-based chemotherapy, specifically nab-paclitaxel (nab-PTX).
  • A 71-year-old man experienced CME in both eyes while being treated for unresectable pancreatic cancer, but his vision improved and CME decreased significantly after stopping the chemotherapy two months later.
  • Oncologists should recognize this potential side effect of nab-PTX to ensure timely referrals to eye specialists, which can help protect patients' vision.

Article Abstract

Cystoid macular edema (CME) is a rare adverse event induced by taxane-based chemotherapy. Here, we describe the case of a 71-year-old man who developed bilateral CME during treatment with nab-paclitaxel (nab-PTX) for unresectable pancreatic cancer. Two months after drug discontinuation, his vision improved, and there was significant reduction in the CME on optical coherence tomography. CME is an adverse event that can be treated with the early withdrawal of nab-PTX. Oncologists who use nab-PTX should be aware of this adverse event for timely patient referral to an ophthalmologist and appropriate treatment that would enable the preservation of the patient's visual acuity.

Download full-text PDF

Source
http://dx.doi.org/10.11405/nisshoshi.118.272DOI Listing

Publication Analysis

Top Keywords

adverse event
12
macular edema
8
[cystoid macular
4
edema secondary
4
secondary albumin-bound
4
albumin-bound paclitaxel
4
paclitaxel therapy
4
therapy pancreatic
4
pancreatic cancer]
4
cancer] cystoid
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!